Emma Winkler to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications Emma Winkler has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0.096
-
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021 04 29; 184(9):2316-2331.e15.
Score: 0.026
-
Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature. 2021 03; 591(7849):293-299.
Score: 0.026
-
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host Microbe. 2021 07 14; 29(7):1151-1161.e5.
Score: 0.007
-
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021 08; 596(7870):103-108.
Score: 0.007
-
Profiling B cell immunodominance after SARS-CoV-2 infection reveals antibody evolution to non-neutralizing viral targets. Immunity. 2021 06 08; 54(6):1290-1303.e7.
Score: 0.007
-
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021 04; 27(4):717-726.
Score: 0.006
-
A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell. 2020 10 01; 183(1):169-184.e13.
Score: 0.006
-
Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 08; 584(7821):443-449.
Score: 0.006
-
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. J Immunol. 2020 08 15; 205(4):915-922.
Score: 0.006